Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33207094

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2020 Nov 19
First author
Shaw AT

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2021 Jan;18(1):6. doi: 10.1038/s41571-020-00458-w.
    note
    Source null
    related pmid
    33262501
    relationship
    Comment in
  2. citation
    Cancer Discov. 2021 Jan;11(1):OF5. doi: 10.1158/2159-8290.CD-NB2020-110.
    note
    Source null
    related pmid
    33298467
    relationship
    Comment in
  3. citation
    Cancer Cell. 2021 Jan 11;39(1):25-27. doi: 10.1016/j.ccell.2020.12.017.
    note
    Source null
    related pmid
    33434512
    relationship
    Comment in
  4. citation
    Strahlenther Onkol. 2021 Jul;197(7):657-660. doi: 10.1007/s00066-021-01788-z.
    note
    Source null
    related pmid
    34110434
    relationship
    Comment in
  5. citation
    Eur J Hosp Pharm. 2023 Jan;30(1):e5. doi: 10.1136/ejhpharm-2021-003018.
    note
    Source null
    related pmid
    34521724
    relationship
    Comment in
  6. citation
    Future Oncol. 2021 Dec 1;17(34):4649-4656. doi: 10.2217/fon-2021-0904.
    note
    Source null
    related pmid
    34585621
    relationship
    Comment in

Authors and identifiers

  1. name
    Shaw AT
    type
    Author
  2. name
    Bauer TM
    type
    Author
  3. name
    de Marinis F
    type
    Author
  4. name
    Felip E
    type
    Author
  5. name
    Goto Y
    type
    Author
  6. name
    Liu G
    type
    Author
  7. name
    Mazieres J
    type
    Author
  8. name
    Kim DW
    type
    Author
  9. name
    Mok T
    type
    Author
  10. name
    Polli A
    type
    Author
  11. name
    Thurm H
    type
    Author
  12. name
    Calella AM
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Shaw AT
    type
    Author
  2. name
    Bauer TM
    type
    Author
  3. name
    de Marinis F
    type
    Author
  4. name
    Felip E
    type
    Author
  5. name
    Goto Y
    type
    Author
  6. name
    Liu G
    type
    Author
  7. name
    Mazieres J
    type
    Author
  8. name
    Kim DW
    type
    Author
  9. name
    Mok T
    type
    Author
  10. name
    Polli A
    type
    Author
  11. name
    Thurm H
    type
    Author
  12. name
    Calella AM
    type
    Author
bibliography ids
  1. nci-bib-48c00802b04e8112f138974c
book metadata
content sha256
2d32e882b4ca8e6c9e2ee6f50ccdc97b74d3fabef0a9050e88e28018df09d688
document type
citation
dois
  1. 10.1056/NEJMoa2027187
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:33207094
immutable id
pubmed:33207094@2d32e882b4ca8e6c9e2ee6f50ccdc97b74d3fabef0a9050e88e28018df09d688
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
21
name
The New England journal of medicine
nlm unique id
0255562
pages
2018-2029
volume
383
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2021 Jan;18(1):6. doi: 10.1038/s41571-020-00458-w.
    note
    Source null
    related pmid
    33262501
    relationship
    Comment in
  2. citation
    Cancer Discov. 2021 Jan;11(1):OF5. doi: 10.1158/2159-8290.CD-NB2020-110.
    note
    Source null
    related pmid
    33298467
    relationship
    Comment in
  3. citation
    Cancer Cell. 2021 Jan 11;39(1):25-27. doi: 10.1016/j.ccell.2020.12.017.
    note
    Source null
    related pmid
    33434512
    relationship
    Comment in
  4. citation
    Strahlenther Onkol. 2021 Jul;197(7):657-660. doi: 10.1007/s00066-021-01788-z.
    note
    Source null
    related pmid
    34110434
    relationship
    Comment in
  5. citation
    Eur J Hosp Pharm. 2023 Jan;30(1):e5. doi: 10.1136/ejhpharm-2021-003018.
    note
    Source null
    related pmid
    34521724
    relationship
    Comment in
  6. citation
    Future Oncol. 2021 Dec 1;17(34):4649-4656. doi: 10.2217/fon-2021-0904.
    note
    Source null
    related pmid
    34585621
    relationship
    Comment in
outcomes validated
false
pmid
33207094
provenance
batch id
9bca82d1bba2b27adc79
provider
NCBI PubMed ESummary
record sha256
8744d083c725a5a4039fd9d9350eeda2b09f621d8b1e61811f955c5e25d33c3e
response sha256
c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
retrieved at
2026-09-09T23:47:56.131551+00:00
publication date
display
2020 Nov 19
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33207094/
title
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

Preserved source evidence · Not medical advice